<DOC>
	<DOC>NCT00141401</DOC>
	<brief_summary>To evaluate long-term efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy.</brief_summary>
	<brief_title>Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must have met the inclusion criteria for preceding doubleblind study Must have received pregabalin or amitriptyline or placebo under doubleblind conditions under doubleblind conditions at least during first 3 weeks if doubleblind treatment phase of preceding study. Patients cannot be included if they experienced a serious adverse event while participating in preceding doubleblind study, which was determined to be related to the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>